Laboratoires Pierre Fabre And Millenia Hope Biopharma Enter Into An Important Collaborative Partnership
Published: Jun 22, 2006
CASTRES, France, and WILMINGTON, Del., June 22 /PRNewswire/ -- Les Laboratoires Pierre Fabre, a privately held company, and Millenia Hope Inc., a Biopharma Corporation , are pleased to announce that Pierre Fabre Medicament and Millenia Hope Biopharma (MHB), the Canadian subsidiary of Millenia Hope Inc., have finalized an important partnership.
The Pierre Fabre Group is a world leader in the discovery, development and commercialization of plant-derived pharmaceutical and dermo-cosmetic products. Incorporating the latest scientific advancements into the products that it brings to the market, the Pierre Fabre Group is committed to products of plant origin.
MHB is a world leader in Phytomics Technologies and is ideally suited through its expertise, technologies, infrastructure and library of phytochemicals to discover, develop and produce new plant-derived products for the health industry.
The Pierre Fabre Group and Millenia Hope Biopharma are pleased to have created this association and look forward to future collaborations.
ABOUT LES LABORATOIRES PIERRE FABRE:
The Pierre Fabre Group (PFG), the second largest independent R&D laboratory in France, employs 8,700 people and had revenues of 1,48 billion euro in 2005, of which 44% was achieved internationally. PFG's activities are focused on ethical, health and dermo-cosmetic products branded with Avene, Ducray, A Derma, Galenic Klorane and Rene Furterer trademarks. Employing more than 1,400 researchers, the Pierre Fabre Group spends 25% of its annual revenues on R&D mainly in five therapeutic fields: oncology (Pierre Fabre Medicaments priority with 50% of total R&D spending), central nervous system, cardiology, internal medicine/urology and dermatology.
ABOUT MILLENIA HOPE:
Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
ABOUT MILLENIA HOPE BIOPHARMA:
Millenia Hope Biopharma (MHB) is the world's leading bioresearch firm in Phytomic Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. MHB has spent over US$25 million in developing its unique Phytomics Technologies, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB is in the midst of commercializing several projects with leading multi-national corporations.
SAFE HARBOR STATEMENTS:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as "forward- looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.
Pierre Fabre; Millenia Hope Inc.Laboratoires
CONTACT: Caroline Perdrix of Laboratoires Pierre Fabre, +33-1-49-10-81-12,firstname.lastname@example.org; or Hugo Valente, CFO of Millenia HopeInc., +1-514-846-5757, +1-514-288-8822, email@example.com